Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific...(the lives of marine species. POST's...)
Navigation Links
Scientists achieve first tracking of salmon from headwaters in Rockies through Pacific to Alaska
Date:10/27/2008
the lives of marine species.
POST's volunteer Management Board, comprised of members from Canadian and American agencies and groups concerned with maintaining the welfare of our oceans and their inhabitants, are constantly seeking novel opportunities to apply the technology and infrastructure.
'/>"/>
| Contact: Terry Collins terrycollins@rogers.com 416-538-8712 Census of Marine Life Source:Eurekalert |
Related biology news :
1. NIAID scientists to speak on range of infectious disease topics at major scientific meeting
2. British scientists go cloud-hopping in the Pacific to improve climate predictions
3. Scientists map soils on an extinct American volcano
4. Scientists call for protected swimways for the endangered leatherback sea turtle
5. Scientists from Granada find a potential treatment to prevent diabetes and obesity
6. Scientists discover bacteria that can cause bone infections
7. Scientists propose the creation of a new type of seed bank
8. EMBO honors 59 leading life scientists
9. Caltech scientists engineer supersensitive receptor, gain better understanding of dopamine system
10. Extreme nature helps scientists design nano materials
11. Forsyth scientists trigger cancer-like response from embryonic stem cells
Post Your Comments:
Breaking Biology News(10 mins):Type 2 diabetes gene predisposes children to obesity 2New understanding of how to prevent destruction of a tumor suppressor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 1Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 2Medifast Inc Named by Forbes as One of Americas 200 Best Small Companies 59631 3APIC Announces Winner of First Healthcare Administrator Award 59628 1APIC Announces Winner of First Healthcare Administrator Award 59628 2APIC Announces Winner of First Healthcare Administrator Award 59628 3Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 1Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 2Wound Management Technologies Announces Clinical Study Presentation of CellerateRx 28R 29 Technology at Leading Skin and Wound Care Conference 59625 3
Other Biology News:Plant studies reveal how, where seeds store iron 2New way of tracking muscle damage from radiation 2
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4
[0] Lyric Presents the Sounds of the Season[0] Super cool atom thermometer[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
Other Biology Technology:Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 3Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 4TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 3TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel 4Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies 2
Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and ProductionTorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of TezampanelIsolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |